Trading a CGEM straddle lets you take a pure volatility position on Cullinan Therapeutics Inc without committing to a direction. Cullinan Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate CGEM straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on CGEM profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Cullinan Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the CGEM straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the CGEM straddle is the cleanest expression of that view. Our scanner prices every CGEM straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a CGEM straddle into a catalyst or short a CGEM straddle to harvest decay, the options straddle setups that matter are all in one place.
